Atlas market file · Equity · United States
Health Catalyst, Inc.HCAT
- Last close
- 1.73
- Change
- -25.11%
- 96-bar range
- 0.955 – 2.4
- As of
- 7 Aug 2026
Health Catalyst, Inc. is a services-computer programming, data processing, etc. issuer listed as HCAT on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
HCAT
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-76.20% over the window).
Source rail: Yahoo Finance chart API (HCAT). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for HCAT. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
HCAT public profile
Services-computer programming, data processing, etc. issuer. Health Catalyst, Inc. is connected to current market context, cited company sources and its retained research file.
Health Catalyst, Inc. trades as HCAT on NASDAQ. Health Catalyst, Inc. (HCAT) has a latest verified close of 1.73, down 25.11%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files HCAT under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Health Catalyst, Inc. today
Health Catalyst, Inc. (HCAT) reported a Q1 2026 net loss of $111.0 million on revenue of $70.8 million, per its SEC 10-Q filing, as the healthcare analytics provider continues to burn cash despite touting AI-driven 'efficiency' solutions for hospitals. The company’s operating loss widened to $106.5 million, with research and development costs alone hitting $9.8 million, even as it acquired Upfront Healthcare Services in early 2025 to expand its patient engagement tools.
HCAT’s business model splits 70% technology revenue and 30% professional services, though neither segment appears capable of staunching the financial bleed. Cash and short-term investments totaled $108.9 million, but net cash from operations was just $18.5 million, raising questions about sustainability. The board’s recent insider share sales, disclosed in four separate 8-K filings on July 20, 2026, further cloud confidence in a turnaround.
The company’s latest 10-Q also highlights risks including 'increasing competition in the healthcare data analytics market' and 'dependence on successful integration of acquisitions.' With liabilities exceeding $274 million and stockholders’ equity at $138.1 million, HCAT’s balance sheet resembles a patient in critical condition-despite its website’s claims of 'regulatory & cybersecurity' expertise. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1636422/000163642226000066/hcat-20260331.htm)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
HCAT technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on HCAT
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep HCAT research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
HCAT FAQ
What is Health Catalyst, Inc. (HCAT)?Health Catalyst, Inc. (HCAT) has a latest verified close of 1.73, down 25.11%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed...
Health Catalyst, Inc. (HCAT) has a latest verified close of 1.73, down 25.11%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for HCAT?Health Catalyst, Inc. (HCAT) has a latest verified close of 1.73, down 25.11%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources,...
Health Catalyst, Inc. (HCAT) has a latest verified close of 1.73, down 25.11%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files HCAT under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the HCAT page updated?The HCAT public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The HCAT public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for HCAT?The HCAT file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:HCAT. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The HCAT file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:HCAT. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on HCAT?Yes. The workstation can open HCAT, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open HCAT, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this HCAT page investment advice?No. The HCAT page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The HCAT page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →